Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takekazu Kubo

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Recent Patents on CNS Drug Discovery|January 29, 2008
Rho-ROCK inhibitors for the treatment of CNS injuryTakekazu Kubo, Toshihide Yamashita
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|December 21, 2011
Repulsive guidance molecule-a and demyelination: implications for multiple sclerosisTakekazu Kubo, Shigeru Tokita, Toshihide Yamashita
Biochemical and Biophysical Research Communications|June 4, 2008
Inhibition of branching and spine maturation by repulsive guidance molecule in cultured cortical neuronsJunko Yoshida, Takekazu Kubo, Toshihide Yamashita
Brain Research. Molecular Brain Research|October 24, 2002
Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)Takekazu Kubo, Satoko Nishimura, Tomiichiro Oda
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 11, 2006
[Therapeutic strategy to promote regeneration of the injured central nervous system]Toshihide Yamashita, Katsuhiko Hata, Atsushi Yamaguchi, et al.
Therapeutics and Clinical Risk Management|October 2, 2008
The therapeutic effects of Rho-ROCK inhibitors on CNS disordersTakekazu Kubo, Atsushi Yamaguchi, Nobuyoshi Iwata, et al.
Current Pharmaceutical Design|August 21, 2007
Rho-ROCK inhibitors as emerging strategies to promote nerve regenerationTakekazu Kubo, Katsuhiko Hata, Atsushi Yamaguchi, et al.
Journal of Neuroscience Research|October 23, 2002
In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patientsTakekazu Kubo, Satoko Nishimura, Yoshihiro Kumagae, et al.
Biochemical and Biophysical Research Communications|October 16, 2010
Th1 cells promote neurite outgrowth from cortical neurons via a mechanism dependent on semaphorinsHiroshi Ishii, Takekazu Kubo, Atsushi Kumanogoh, et al.
Journal of Neuropathology and Experimental Neurology|March 18, 2003
Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer diseaseTakekazu Kubo, Yoshihiro Kumagae, Carol A Miller, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Recent Patents on CNS Drug Discovery|January 29, 2008
Rho-ROCK inhibitors for the treatment of CNS injuryTakekazu Kubo, Toshihide Yamashita
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|December 21, 2011
Repulsive guidance molecule-a and demyelination: implications for multiple sclerosisTakekazu Kubo, Shigeru Tokita, Toshihide Yamashita
Biochemical and Biophysical Research Communications|June 4, 2008
Inhibition of branching and spine maturation by repulsive guidance molecule in cultured cortical neuronsJunko Yoshida, Takekazu Kubo, Toshihide Yamashita
Brain Research. Molecular Brain Research|October 24, 2002
Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)Takekazu Kubo, Satoko Nishimura, Tomiichiro Oda
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 11, 2006
[Therapeutic strategy to promote regeneration of the injured central nervous system]Toshihide Yamashita, Katsuhiko Hata, Atsushi Yamaguchi, et al.
Therapeutics and Clinical Risk Management|October 2, 2008
The therapeutic effects of Rho-ROCK inhibitors on CNS disordersTakekazu Kubo, Atsushi Yamaguchi, Nobuyoshi Iwata, et al.
Current Pharmaceutical Design|August 21, 2007
Rho-ROCK inhibitors as emerging strategies to promote nerve regenerationTakekazu Kubo, Katsuhiko Hata, Atsushi Yamaguchi, et al.
Journal of Neuroscience Research|October 23, 2002
In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patientsTakekazu Kubo, Satoko Nishimura, Yoshihiro Kumagae, et al.
Biochemical and Biophysical Research Communications|October 16, 2010
Th1 cells promote neurite outgrowth from cortical neurons via a mechanism dependent on semaphorinsHiroshi Ishii, Takekazu Kubo, Atsushi Kumanogoh, et al.
Journal of Neuropathology and Experimental Neurology|March 18, 2003
Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer diseaseTakekazu Kubo, Yoshihiro Kumagae, Carol A Miller, et al.
Pageof 4